<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jorg Dietrich, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>High-grade gliomas are malignant, often rapidly progressive primary brain tumors. The most common high-grade gliomas in adults are isocitrate dehydrogenase (IDH)-wildtype glioblastoma (grade 4), grade 3 and 4 IDH-mutant astrocytoma, and grade 3 IDH-mutant, 1p/19q-codeleted oligodendroglioma. (See  <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Histopathologic and molecular classification'</a>.)</p><p>The clinical manifestations, prognostic factors, and initial surgical approach to patients with high-grade gliomas will be reviewed here.</p><p>Other patient management topics that are covered separately include:</p><p class="bulletIndent1"><span class="glyph">●</span>The diagnostic approach to patients with suspected brain tumors (see  <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjuvant radiation therapy and chemotherapy following initial surgery (see  <a class="medical medical_review" href="/z/d/html/5225.html" rel="external">"Radiation therapy for high-grade gliomas"</a> and  <a class="medical medical_review" href="/z/d/html/5207.html" rel="external">"Initial treatment and prognosis of IDH-wildtype glioblastoma in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative therapy for IDH-mutant astrocytomas (see  <a class="medical medical_review" href="/z/d/html/5198.html" rel="external">"Treatment and prognosis of IDH-mutant astrocytomas in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative therapy for oligodendrogliomas (see  <a class="medical medical_review" href="/z/d/html/5221.html" rel="external">"Treatment and prognosis of IDH-mutant, 1p/19q-codeleted oligodendrogliomas in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glioblastoma in older adults (see  <a class="medical medical_review" href="/z/d/html/15246.html" rel="external">"Management of glioblastoma in older adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent high-grade gliomas (see  <a class="medical medical_review" href="/z/d/html/5205.html" rel="external">"Management of recurrent high-grade gliomas"</a>)</p><p></p><p class="headingAnchor" id="H2597691"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Patients with high-grade glioma typically present with subacute neurologic signs and symptoms that progress over days to weeks and vary according to the location of the tumor within the brain. Magnetic resonance imaging (MRI) of the brain provides confirmatory evidence of a mass lesion, but a tissue diagnosis is ultimately required to distinguish high-grade gliomas from other primary and metastatic brain tumors.</p><p class="headingAnchor" id="H2"><span class="h2">Presenting signs and symptoms</span><span class="headingEndMark"> — </span>The presenting signs and symptoms of high-grade gliomas are dependent upon the location and size of the lesion and are similar to those produced by other primary and metastatic brain tumors. Patients typically present with progressive neurologic symptoms that evolve over the course of days to weeks. (See  <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults"</a>.)</p><p>Among patients with high-grade gliomas, the most common presenting symptoms include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Headache (50 to 60 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures (20 to 50 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focal neurologic symptoms such as memory loss, motor weakness, visual symptoms, language deficit, and cognitive and personality changes (10 to 40 percent)</p><p></p><p>Focal neurologic deficits are more common with glioblastoma compared with lower-grade gliomas, whereas seizures occur less frequently as a presenting symptom of glioblastoma than with lower-grade gliomas. Large tumors may be associated with significant edema, mass effect, and increased intracranial pressure. (See  <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults", section on 'Increased intracranial pressure'</a>.)</p><p>Rarely, high-grade gliomas can present with meningeal dissemination [<a href="#rid2">2,3</a>]. This finding is more commonly diagnosed later in the natural history of the disease or at autopsy [<a href="#rid4">4,5</a>]. Presenting symptoms of meningeal gliomatosis are back pain with or without radicular symptoms, mental status changes, cranial nerve palsies, myelopathy, cauda equina syndrome, and headache with symptomatic hydrocephalus.</p><p class="headingAnchor" id="H3083557080"><span class="h2">Family history and risk factors</span><span class="headingEndMark"> — </span>The vast majority of patients with high-grade glioma have no family history of brain tumors or identifiable risk factors for glioma.</p><p>In rare cases, glioblastoma and other high-grade gliomas are a manifestation of a tumor predisposition syndrome such as Li-Fraumeni syndrome, Lynch syndrome (hereditary nonpolyposis colorectal cancer), or constitutional mismatch repair-deficiency syndrome. In most of these cases, the family history is notable for multiple first- and second-degree family members with early-onset cancers. Such patients are typically offered a referral for genetic counseling. Little is known about the genetic factors underlying apparently sporadic high-grade gliomas and families with clustering of brain tumors in the absence of a recognized genetic syndrome. (See  <a class="medical medical_review" href="/z/d/html/5214.html" rel="external">"Risk factors for brain tumors", section on 'Genetic predisposition syndromes'</a>.)</p><p>Aside from genetic factors, the only established risk factor for glioblastoma and other high-grade gliomas is exposure to ionizing radiation, as occurs from therapeutic radiation therapy for childhood brain tumors or leukemia. The latency between irradiation and the development of a glioma varies from five years to several decades. Data on other environmental exposures including electromagnetic radiation, radiofrequency radiation from cell phones, and head trauma are inconclusive. (See  <a class="medical medical_review" href="/z/d/html/5214.html" rel="external">"Risk factors for brain tumors", section on 'Ionizing radiation'</a>.)</p><p class="headingAnchor" id="H2597782"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Contrast-enhanced MRI is superior to computed tomography (CT) for the characterization of brain tumors.</p><p>On MRI, high-grade gliomas are typically hypointense on T1-weighted images and enhance heterogeneously following contrast administration. Glioblastomas typically have a pattern of intense rim enhancement with central clearing, indicative of necrosis  (<a class="graphic graphic_diagnosticimage graphicRef113733" href="/z/d/graphic/113733.html" rel="external">image 1</a>). Enhancing tumor can be distinguished from the surrounding hypointense signal of edema on T1-weighted sequences  (<a class="graphic graphic_diagnosticimage graphicRef65860" href="/z/d/graphic/65860.html" rel="external">image 2</a>). Regardless of the histologic grade, high-grade gliomas generally show increased T2 and fluid-attenuated inversion recovery (FLAIR) signal intensity; however, some grade 3 gliomas do not manifest contrast enhancement [<a href="#rid6">6</a>].</p><p>Many high-grade gliomas are characterized by areas of infiltrative, nonenhancing tumor that may be multifocal. Infiltrative tumor typically appears as expansile T2 hyperintense signal abnormality involving both cortex and underlying white matter. Such areas may or may not be contiguous with enhancing portions of the tumor. Grade 3 (anaplastic) oligodendrogliomas may have areas of internal calcification. (See  <a class="medical medical_review" href="/z/d/html/5186.html" rel="external">"Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas", section on 'Neuroimaging'</a>.)</p><p>On magnetic resonance spectroscopy (MRS), high-grade gliomas are typically characterized by increased choline and decreased N-acetylaspartate. Evidence of increased blood volume is often present on magnetic resonance perfusion imaging. Like other malignancies, high-grade gliomas have increased metabolic activity and usually show increased uptake of fluorodeoxyglucose on positron emission tomography (PET).</p><p class="headingAnchor" id="H1473706376"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>Patients with a suspected high-grade glioma should undergo history and physical examination to evaluate for symptoms and neurologic deficits associated with the tumor. The degree of deficits and the clinical stability of the patient guide the urgency of neurosurgical evaluation and treatment and need for corticosteroids. (See  <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults", section on 'Role of glucocorticoids'</a>.)</p><p>Brain MRI with contrast is often the only study required preoperatively. Patients with a contraindication to brain MRI should undergo head CT with contrast. Screening for systemic malignancy is not necessary when the clinical and radiographic suspicion for high-grade glioma is high  (<a class="graphic graphic_algorithm graphicRef113770" href="/z/d/graphic/113770.html" rel="external">algorithm 1</a>). The initial evaluation and differential diagnosis of brain tumors in adults is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults"</a>.)</p><p>Patients presenting with a seizure or who have a history suggestive of previously unreported or unrecognized seizures should be treated with an antiseizure medication. Prophylactic antiseizure medications in patients who have not had a seizure are not indicated outside of the perioperative period [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/5181.html" rel="external">"Seizures in patients with primary and metastatic brain tumors", section on 'Approach to management'</a> and  <a class="medical medical_review" href="/z/d/html/5181.html" rel="external">"Seizures in patients with primary and metastatic brain tumors", section on 'Indications for antiseizure medication therapy'</a>.)</p><p>A tissue diagnosis in patients with a presumed high-grade glioma is essential. This can be accomplished either at the time of surgical resection or in a separate biopsy procedure. Biopsy alone is used in situations where the lesion is not amenable to resection, a meaningful amount of tumor tissue cannot be removed, or the patient's overall clinical condition will not permit surgery. In the remaining cases, maximal safe resection is the preferred initial approach to both diagnosis and management. For patients who undergo surgery, repeat brain MRI should be obtained within 24 to 48 hours postoperatively to determine the extent of resection. (See <a class="local">'Deep-seated or multifocal tumors'</a> below and <a class="local">'Surgically accessible tumors'</a> below.)</p><p class="headingAnchor" id="H1603685208"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Gliomas are classified based not only on histopathologic appearance but also on molecular parameters, including isocitrate dehydrogenase (IDH) mutation status and the presence or absence of 1p/19q codeletion  (<a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef115919" href="/z/d/graphic/115919.html" rel="external">table 2</a>) [<a href="#rid8">8,9</a>]. Astrocytic and oligodendroglial tumors are grouped together as diffuse gliomas, on the basis of growth pattern, behavior, and shared IDH genetic status  (<a class="graphic graphic_algorithm graphicRef134946" href="/z/d/graphic/134946.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H1255477626"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>Astrocytic tumors are composed of cells with elongated or irregular, hyperchromatic nuclei and eosinophilic, glial fibrillary acidic protein (GFAP)-positive cytoplasm. By contrast, oligodendrogliomas have rounded nuclei, often with perinuclear halos, calcification, and delicate, branching blood vessels  (<a class="graphic graphic_picture graphicRef65601" href="/z/d/graphic/65601.html" rel="external">picture 1</a>). As tumors increase in histologic grade, additional features of malignancy are noted. In general, nuclear atypia and increased mitotic activity characterize grade 3 (anaplastic) tumors  (<a class="graphic graphic_picture graphicRef73766" href="/z/d/graphic/73766.html" rel="external">picture 2</a>), while microvascular proliferation and necrosis define grade 4 tumors (eg, glioblastoma)  (<a class="graphic graphic_picture graphicRef67180" href="/z/d/graphic/67180.html" rel="external">picture 3</a>). (See  <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'General features'</a>.)</p><p class="headingAnchor" id="H481970764"><span class="h2">Key molecular tests</span><span class="headingEndMark"> — </span>Molecular characterization of gliomas is critical for accurate diagnosis, prognostication, and treatment [<a href="#rid10">10</a>]. Routine pathologic evaluation of high-grade glioma specimens should include IDH mutational testing and, in selected cases, testing for 1p/19q codeletion to allow for an integrated diagnosis  (<a class="graphic graphic_algorithm graphicRef134946" href="/z/d/graphic/134946.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">table 1</a>). (See <a class="local">'Integrated diagnosis'</a> below.)</p><p>Immunohistochemistry (IHC) for the most common IDH mutation in gliomas, <em>IDH1</em> R132H, captures approximately 90 percent of IDH mutations in gliomas. If R132H-mutant IDH1 IHC is negative, sequencing of <em>IDH1</em> and <em>IDH2</em> should be prioritized in all patients with grade 3 gliomas and in younger patients (&lt;55 years) with suspected glioblastoma, as the distinction between IDH-mutant and IDH-wildtype tumors has prognostic implications and is central to an integrated diagnosis. Sequencing of IDH in patients with glioblastoma who are older than 55 years is not required because IDH mutations in glioblastoma are considered rare in this age group.</p><p>Testing for 1p/19q codeletion is indicated in all tumors with oligodendroglial histopathologic features. An integrated diagnosis of both grade 2 and grade 3 (anaplastic) oligodendroglioma requires confirmation of 1p/19q codeletion as well as mutant <em>IDH1</em> or <em>IDH2 </em> (<a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">table 1</a>). In IDH-mutant gliomas, homozygous deletion of cyclin-dependent kinase inhibitor 2A/B (<em>CDKN2A/B</em>) is a negative prognostic marker and establishes a higher grade, independent of histologic features. (See  <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on '1p/19q codeletion'</a>.)</p><p>Glioblastoma specimens of sufficient size should also be tested for O6-methylguanine-DNA methyltransferase (<em>MGMT</em>) promoter methylation status. While not required for diagnosis, results are useful for prognostication and are predictive of response to alkylating-agent chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/5207.html" rel="external">"Initial treatment and prognosis of IDH-wildtype glioblastoma in adults", section on 'MGMT methylation status'</a>.)</p><p>Additional testing that can provide useful information in the characterization of high-grade gliomas is summarized in the table  (<a class="graphic graphic_table graphicRef115919" href="/z/d/graphic/115919.html" rel="external">table 2</a>) and discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"</a>.)</p><p class="headingAnchor" id="H3726006740"><span class="h2">Integrated diagnosis</span><span class="headingEndMark"> — </span>The 2021 WHO classification classifies diffuse gliomas in adults according to histopathologic and molecular features [<a href="#rid8">8</a>]. Diffuse gliomas are subdivided into IDH-mutant and IDH-wildtype tumors; within each category exist various tumor grades according to histopathologic features. The most commonly encountered high-grade gliomas include  (<a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Glioblastoma, IDH-wildtype</p><p class="bulletIndent1"><span class="glyph">●</span>Astrocytoma, IDH-mutant, grade 4</p><p class="bulletIndent1"><span class="glyph">●</span>Astrocytoma, IDH-mutant, grade 3</p><p class="bulletIndent1"><span class="glyph">●</span>Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3</p><p></p><p>The diagnosis of mixed oligoastrocytoma no longer exists for fully characterized tumors. Tumors with mixed histology require information on both IDH and 1p/19q codeletion status to be categorized as either astrocytoma or oligodendroglioma based on their molecular signature. (See  <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Oligoastrocytoma (historical entity)'</a>.)</p><p>The pathologic diagnosis of gliomas is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Histopathologic and molecular classification'</a>.)</p><p class="headingAnchor" id="H3035676999"><span class="h2">Role of tumor genome sequencing</span><span class="headingEndMark"> — </span>Next-generation sequencing panels on cancer specimens have become more affordable and more widely available; however, routine sequencing of glioma specimens is yet to be proven to be of clinical benefit [<a href="#rid11">11</a>].</p><p>Panels tailored for glioma specimens often include screening for the most frequent cancer genes, some of which are occasionally identified in glioblastoma (eg, <em>BRAF</em> V600E) and may allow access to clinical trials of relevant targeted drugs [<a href="#rid12">12-14</a>]. Screening for oncogenic gene fusions, such as neurotrophic receptor tyrosine kinase (<em>NTRK</em>) fusions or fibroblast growth factor receptor 3-transforming acidic coiled-coil containing protein 3 (<em>FGFR3-TACC3</em>), can also identify relevant targets [<a href="#rid15">15-17</a>]. (See  <a class="medical medical_review" href="/z/d/html/5205.html" rel="external">"Management of recurrent high-grade gliomas", section on 'Genotype-directed therapies'</a>.)</p><p class="headingAnchor" id="H3761081723"><span class="h1">SURGERY</span></p><p class="headingAnchor" id="H5"><span class="h2">Deep-seated or multifocal tumors</span><span class="headingEndMark"> — </span>The combined use of computerized imaging and stereotactic devices has allowed neurosurgeons to perform deep brain biopsies with accurate tumor localization. Frameless stereotaxy establishes a computerized link between the preoperative three-dimensional tumor volume and the surface landmarks of the patient. This link permits the neurosurgeon to be aware of the three-dimensional position of surgical instruments within the intracranial space during the biopsy based upon the preoperative imaging.</p><p>Stereotactic image-guided brain biopsy is an accurate and safe diagnostic procedure in patients with focal lesions in nonresectable areas of the brain such as the basal ganglia or thalamus. Diagnostic yield is approximately 90 percent. Complications occur in up to 15 percent of cases, most commonly transient neurologic deficits (10 percent), biopsy-site hemorrhage (8 percent), and permanent neurologic deficits (4 percent) [<a href="#rid18">18</a>]. The procedure-related mortality rate is 1 to 2 percent. Although rare, tumor seeding along the stereotactic biopsy tract has been described [<a href="#rid19">19,20</a>].</p><p>For tumors that contain both enhancing and nonenhancing components, biopsy should target the enhancing areas in an effort to obtain diagnostic tissue that is representative of the highest-grade portion of the tumor.</p><p>Both positron emission tomography (PET) and magnetic resonance spectroscopy (MRS) have been used to identify metabolically active areas of tumor, thereby increasing the accuracy of stereotactic brain biopsy [<a href="#rid21">21-24</a>]. These techniques are primarily research tools and are not in widespread clinical use for this purpose, as structural MRI typically provides sufficient information to guide optimal biopsy site.</p><p class="headingAnchor" id="H7"><span class="h2">Surgically accessible tumors</span><span class="headingEndMark"> — </span>The initial treatment for high-grade gliomas in accessible locations is resection [<a href="#rid25">25</a>]. Maximal resection with preservation of neurologic function is an important goal in the initial management of patients with high-grade gliomas, and the extent of surgery must be balanced with preservation of neurologic function.</p><p>The available observational evidence suggests that aggressive resection is associated with improved functional status and possibly with prolonged survival [<a href="#rid26">26,27</a>]. Various preoperative and intraoperative advances are being incorporated into patient management to facilitate these goals. (See <a class="local">'Extent of resection'</a> below.)</p><p>A review of over 38,000 surgical admissions for supratentorial brain tumors from the Nationwide Inpatient Sample between 1988 and 2000 showed three important trends: decreasing inpatient mortality over time for brain tumor operations, centralization of care with higher-volume centers performing an ever larger percentage of all such surgeries, and reduced mortality at high-volume hospitals [<a href="#rid28">28</a>]. For craniotomy, mortality at hospitals with five or fewer admissions per year was 4.5 percent, compared with 1.5 percent at hospitals with 42 or more admissions per year. It is not known whether these trends affect long-term outcome.</p><p class="headingAnchor" id="H8"><span class="h3">Preoperative imaging</span><span class="headingEndMark"> — </span>Preoperative functional MRI and diffusion tractography may be used to optimize tumor volume definition and minimize operative injury to eloquent (eg, speech and motor) areas by allowing preoperative definition of affected and normal brain areas and functional mapping of brain tissue [<a href="#rid29">29-32</a>]. In addition to localization of functional cortical areas such as motor cortex via functional MRI, diffusion tensor imaging enables the visualization of subcortical tracts that carry eloquent task information from speech, motor, and visual pathways [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Intraoperative techniques</span><span class="headingEndMark"> — </span>Several intraoperative techniques are used to improve the extent of surgical resection while minimizing collateral damage to normal brain [<a href="#rid34">34</a>]. In some cases, tumors that appear inoperable on preoperative functional imaging are amenable to a substantial amount of safe resection using intraoperative techniques including direct electrical stimulation [<a href="#rid35">35</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Awake craniotomy </strong>–<strong> </strong>For tumors located in eloquent areas, awake craniotomy combining frameless computer-guided stereotaxis with intraoperative direct electrical stimulation and repetitive neurologic and language assessments may facilitate aggressive resection while minimizing postoperative neurologic dysfunction [<a href="#rid35">35-37</a>]. Traditionally, this approach has used repetitive testing, with resection discontinued at the first evidence of neurologic dysfunction. Alternatively, local stimulation has been used to induce language dysfunction, with tumor resection proceeding only in areas not involving language centers. (See  <a class="medical medical_review" href="/z/d/html/94288.html" rel="external">"Anesthesia for awake craniotomy", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intraoperative MRI</strong> – Specially designed operating rooms that are equipped with MRI can guide the resection in "real time." In contrast to frame-based or frameless stereotaxy, this advancement allows actual assessment of tumor volume in its current anatomic location, rather than relying on preoperative data [<a href="#rid38">38</a>]. Intraoperative imaging is used to identify residual tumor after the initial resection and thus can be used to guide further surgery. Such techniques have been shown to increase the proportion of patients that have a gross total resection on postoperative MRI but may not necessarily improve survival in patients with high-grade gliomas [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">The effectiveness of intraoperative MRI was assessed in a trial in which 58 patients were randomly assigned to surgery with or without intraoperative MRI [<a href="#rid40">40</a>]. At surgery, 49 patients had high-grade gliomas and were evaluable. In 8 of 24 cases using intraoperative MRI, imaging revealed residual tumor and led to additional tumor resection. Overall, significantly more patients managed with intraoperative MRI had a complete resection compared with those managed without MRI (96 versus 68 percent). There was no increase in neurologic deficits with this more aggressive surgical approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>5-aminolevulinic acid (ALA)</strong> – Some centers have expertise in the use of ALA, which is an oral optical imaging agent that helps to visualize malignant tissue during surgery with use of specialized surgical microscopes and light source filters [<a href="#rid41">41</a>]. ALA was approved by the US Food and Drug Administration in 2017 for use as an intraoperative agent in patients with suspected high-grade glioma [<a href="#rid42">42</a>]. Similar to intraoperative MRI, use of ALA as an adjunct to surgery improves intraoperative tumor visualization and thus enables greater extent of resection [<a href="#rid43">43-48</a>]. ALA can be combined with other operative techniques, including intraoperative MRI, to help achieve maximal resection with preservation of neurologic function [<a href="#rid49">49</a>].</p><p></p><p>Despite these advances in surgical techniques, local recurrences are frequent even in patients undergoing an apparently complete removal of the tumor. High-grade gliomas are characterized by poorly defined tumor margins with infiltration of neoplastic cells along white matter fibers and the perivascular spaces, which can extend well beyond the tumor margin as defined by the surgeon or by radiographic studies.</p><p class="headingAnchor" id="H10"><span class="h3">Extent of resection</span><span class="headingEndMark"> — </span>The goal of surgery in patients with high-grade glioma is to confirm a pathologic diagnosis and achieve maximal safe resection consistent with preservation of neurologic function. Gliomas are infiltrative tumors, and resection requires removal of both tumor and involved brain tissue. The feasibility of resection depends heavily on the location of the tumor in relation to eloquent cortex.</p><p>In the absence of randomized trials, a large body of observational data suggests that extent of resection is a strong prognostic factor in patients with high-grade glioma, even after adjusting for variables known to be related to both surgical decision-making and outcome, such as age, functional status, and tumor size and location [<a href="#rid26">26,43,44,50-60</a>].</p><p>As an example, in a Surveillance, Epidemiology, and End Results (SEER) registry study that included over 20,000 adults with glioblastoma diagnosed between 1998 and 2009, extent of resection was categorized as gross total resection, subtotal resection (including partial resection and excisional biopsy), or no surgery [<a href="#rid61">61</a>]. Thirty percent of the cohort underwent gross total resection, and the likelihood of undergoing gross total resection decreased with advancing age. Compared with subtotal resection, gross total resection was associated with an approximately two- to three-month improvement in overall survival across all age groups. For patients age 45 to 59 years, for example, median overall survival times after gross total resection, subtotal resection, and no surgery were 15, 12, and 7 months, respectively (adjusted hazard ratio [HR] for gross total versus subtotal resection 0.82, 95% CI 0.77-0.89).</p><p>Other studies have attempted to determine whether a survival benefit may exist for significant subtotal resection of the gadolinium-enhancing portions of the tumor, for cases in which gross total resection is not possible. In retrospective analyses of hundreds of surgical cases, a survival benefit has been suggested for resections above a threshold of 70 to 80 percent [<a href="#rid62">62</a>]. For glioblastoma, a four-tiered categorization of extent of resection based on the amount of enhancing and nonenhancing residual tumor volume has been proposed [<a href="#rid63">63</a>].</p><p>The presence of a mutation in isocitrate dehydrogenase (<em>IDH</em>) type 1 or type 2 may be another factor relevant to the association between extent of resection and overall survival. In one large series of high-grade astrocytomas, maximal resection of both enhancing and nonenhancing total tumor volume conferred a significant survival advantage for <em>IDH1</em>-mutant tumors; for <em>IDH1</em>-wildtype tumors, complete resection of enhancing tumor volume but not total tumor volume was associated with improved survival [<a href="#rid64">64</a>]. Others have suggested that age is more important than <em>IDH1/2</em> status, and that maximal resection of nonenhancing plus enhancing tumor volume confers improved survival in younger patients (age ≤65 years) with glioblastoma, independent of <em>IDH1/2</em> status [<a href="#rid59">59</a>].</p><p>Beyond survival, potential benefits of maximal resection rather than biopsy also include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Resection rather than biopsy provides a larger, more representative sample for detailed analysis, thereby increasing the likelihood of an accurate diagnosis, which can help to direct further therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Debulking surgery may facilitate rapid tapering and discontinuation of corticosteroids, thereby reducing the likelihood of steroid-related complications.</p><p></p><p class="headingAnchor" id="H1160967579"><span class="h3">Limited role of carmustine wafers</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">Carmustine</a> polymer wafers (Gliadel) implanted at the time of surgical resection of high-grade glioma have been approved for use by regulatory agencies [<a href="#rid65">65</a>]. They have not been directly compared with concurrent and adjuvant <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, and data are lacking to support a clear survival advantage in patients with newly diagnosed glioblastoma. In addition, the safety of carmustine wafers in combination with radiation plus temozolomide has not been fully established, and some patients develop significant peritumoral edema after wafer placement [<a href="#rid66">66-69</a>]. We therefore do not recommend use of carmustine polymer wafers in patients with newly diagnosed glioblastoma outside of the context of a clinical trial.</p><p>Experience with <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">carmustine</a> wafers in recurrent high-grade glioma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5205.html" rel="external">"Management of recurrent high-grade gliomas", section on 'Reoperation'</a>.)</p><p class="headingAnchor" id="H4089020229"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/130511.html" rel="external">"Society guideline links: Primary brain tumors"</a>.)</p><p class="headingAnchor" id="H624624237"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15364.html" rel="external">"Patient education: Brain cancer (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/17217.html" rel="external">"Patient education: Astrocytoma (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/82941.html" rel="external">"Patient education: Glioblastoma (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/857.html" rel="external">"Patient education: Low-grade glioma in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/855.html" rel="external">"Patient education: High-grade glioma in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/853.html" rel="external">"Patient education: Meningioma (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-grade glioma</strong> – High-grade gliomas are malignant, often rapidly progressive primary brain tumors. The most common high-grade gliomas in adults are isocitrate dehydrogenase (IDH)-wildtype glioblastoma (grade 4), grade 3 and 4 IDH-mutant astrocytoma, and grade 3 IDH-mutant, 1p/19q-codeleted oligodendroglioma  (<a class="graphic graphic_algorithm graphicRef134946" href="/z/d/graphic/134946.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with high-grade glioma present with neurologic signs and symptoms that vary according to the location of the tumor within the brain. MRI of the brain provides confirmatory evidence of a mass lesion, but a tissue diagnosis is ultimately required to distinguish high-grade gliomas from other primary and metastatic brain tumors. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative evaluation</strong> – Brain MRI with contrast is often the only study required preoperatively. Patients with a contraindication to brain MRI should undergo a brain CT with contrast. Screening for systemic malignancy is not necessary when the clinical and radiographic suspicion for high-grade glioma is high. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic diagnosis</strong> – A histologic diagnosis is required for optimal treatment of patients with brain tumors. This can be accomplished either at the time of surgical resection or by more limited biopsy. (See <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical resection</strong> – For patients with a newly diagnosed high-grade glioma, we recommend maximal surgical resection with preservation of neurologic function rather than biopsy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Although gross total resection is preferred whenever possible, subtotal resection or biopsy alone may be required depending upon the location and extent of the tumor. (See <a class="local">'Deep-seated or multifocal tumors'</a> above and <a class="local">'Surgically accessible tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative imaging</strong> – For patients who undergo surgery, a brain MRI should be obtained within 24 to 48 hours postoperatively to determine the extent of resection. (See <a class="local">'Extent of resection'</a> above.)</p><p></p><p class="headingAnchor" id="H3555714661"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William T Curry, Jr, MD, and Tracy Batchelor, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293:557.</a></li><li><a class="nounderline abstract_t">Wheen LC, Anderson NE, Baker PC, et al. Leptomeningeal infiltration as the presenting manifestation of a malignant glioma. J Clin Neurosci 2006; 13:298.</a></li><li><a class="nounderline abstract_t">Cho TA, Chi AS, Schaefer PW, Louis DN. Case records of the Massachusetts General Hospital. Case 8-2014. A 29-year-old man with headache, vomiting, and diplopia. N Engl J Med 2014; 370:1049.</a></li><li><a class="nounderline abstract_t">Wagner S, Benesch M, Berthold F, et al. Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer 2006; 95:991.</a></li><li><a class="nounderline abstract_t">Narin O, Drappatz J, Doherty LM, et al. Cerebrospinal fluid spread of anaplastic glioma. J Clin Oncol 2007; 25:596.</a></li><li><a class="nounderline abstract_t">Scott JN, Brasher PM, Sevick RJ, et al. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002; 59:947.</a></li><li><a class="nounderline abstract_t">Walbert T, Harrison RA, Schiff D, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021; 23:1835.</a></li><li class="breakAll">WHO Classification of Tumours Editorial Board. Thoracic Tumours. In: WHO Classification of Tumours, 5th ed, IARC Publications, 2021. Vol 5.</li><li><a class="nounderline abstract_t">Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23:1231.</a></li><li><a class="nounderline abstract_t">Velázquez Vega JE, Brat DJ, Ryken TC, Olson JJ. The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2020; 150:143.</a></li><li><a class="nounderline abstract_t">van den Bent MJ, Weller M, Wen PY, et al. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol 2017; 19:614.</a></li><li><a class="nounderline abstract_t">Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373:726.</a></li><li><a class="nounderline abstract_t">Kaley T, Touat M, Subbiah V, et al. BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study. J Clin Oncol 2018; 36:3477.</a></li><li><a class="nounderline abstract_t">Lim-Fat MJ, Song KW, Iorgulescu JB, et al. Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. J Neurooncol 2021; 152:515.</a></li><li><a class="nounderline abstract_t">Ziegler DS, Wong M, Mayoh C, et al. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. Br J Cancer 2018; 119:693.</a></li><li><a class="nounderline abstract_t">Nelson KN, Meyer AN, Wang CG, Donoghue DJ. Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling. Oncotarget 2018; 9:34306.</a></li><li><a class="nounderline abstract_t">Frattini V, Pagnotta SM, Tala, et al. A metabolic function of FGFR3-TACC3 gene fusions in cancer. Nature 2018; 553:222.</a></li><li><a class="nounderline abstract_t">Woodworth GF, McGirt MJ, Samdani A, et al. Frameless image-guided stereotactic brain biopsy procedure: diagnostic yield, surgical morbidity, and comparison with the frame-based technique. J Neurosurg 2006; 104:233.</a></li><li><a class="nounderline abstract_t">Steinmetz MP, Barnett GH, Kim BS, et al. Metastatic seeding of the stereotactic biopsy tract in glioblastoma multiforme: case report and review of the literature. J Neurooncol 2001; 55:167.</a></li><li><a class="nounderline abstract_t">Perrin RG, Bernstein M. Iatrogenic seeding of anaplastic astrocytoma following stereotactic biopsy. J Neurooncol 1998; 36:243.</a></li><li><a class="nounderline abstract_t">Pirotte B, Goldman S, Massager N, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 2004; 45:1293.</a></li><li><a class="nounderline abstract_t">McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002; 97:794.</a></li><li><a class="nounderline abstract_t">Hall WA, Liu H, Maxwell RE, Truwit CL. Influence of 1.5-Tesla intraoperative MR imaging on surgical decision making. Acta Neurochir Suppl 2003; 85:29.</a></li><li><a class="nounderline abstract_t">Herminghaus S, Dierks T, Pilatus U, et al. Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg 2003; 98:74.</a></li><li><a class="nounderline abstract_t">Domino JS, Ormond DR, Germano IM, et al. Cytoreductive surgery in the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update. J Neurooncol 2020; 150:121.</a></li><li><a class="nounderline abstract_t">Brown TJ, Brennan MC, Li M, et al. Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol 2016; 2:1460.</a></li><li><a class="nounderline abstract_t">Trifiletti DM, Alonso C, Grover S, et al. Prognostic Implications of Extent of Resection in Glioblastoma: Analysis from a Large Database. World Neurosurg 2017; 103:330.</a></li><li><a class="nounderline abstract_t">Barker FG 2nd, Curry WT Jr, Carter BS. Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care. Neuro Oncol 2005; 7:49.</a></li><li><a class="nounderline abstract_t">Pirotte B, Goldman S, Dewitte O, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 2006; 104:238.</a></li><li><a class="nounderline abstract_t">Krishnan R, Raabe A, Hattingen E, et al. Functional magnetic resonance imaging-integrated neuronavigation: correlation between lesion-to-motor cortex distance and outcome. Neurosurgery 2004; 55:904.</a></li><li><a class="nounderline abstract_t">Ganslandt O, Buchfelder M, Hastreiter P, et al. Magnetic source imaging supports clinical decision making in glioma patients. Clin Neurol Neurosurg 2004; 107:20.</a></li><li><a class="nounderline abstract_t">Luna LP, Sherbaf FG, Sair HI, et al. Can Preoperative Mapping with Functional MRI Reduce Morbidity in Brain Tumor Resection? A Systematic Review and Meta-Analysis of 68 Observational Studies. Radiology 2021; 300:338.</a></li><li><a class="nounderline abstract_t">Kamada K, Todo T, Masutani Y, et al. Visualization of the frontotemporal language fibers by tractography combined with functional magnetic resonance imaging and magnetoencephalography. J Neurosurg 2007; 106:90.</a></li><li><a class="nounderline abstract_t">Jenkinson MD, Barone DG, Bryant A, et al. Intraoperative imaging technology to maximise extent of resection for glioma. Cochrane Database Syst Rev 2018; 1:CD012788.</a></li><li><a class="nounderline abstract_t">Southwell DG, Birk HS, Han SJ, et al. Resection of gliomas deemed inoperable by neurosurgeons based on preoperative imaging studies. J Neurosurg 2018; 129:567.</a></li><li><a class="nounderline abstract_t">Hervey-Jumper SL, Li J, Lau D, et al. Awake craniotomy to maximize glioma resection: methods and technical nuances over a 27-year period. J Neurosurg 2015; 123:325.</a></li><li><a class="nounderline abstract_t">Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. N Engl J Med 2008; 358:18.</a></li><li><a class="nounderline abstract_t">Kubben PL, ter Meulen KJ, Schijns OE, et al. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol 2011; 12:1062.</a></li><li><a class="nounderline abstract_t">Fountain DM, Bryant A, Barone DG, et al. Intraoperative imaging technology to maximise extent of resection for glioma: a network meta-analysis. Cochrane Database Syst Rev 2021; 1:CD013630.</a></li><li><a class="nounderline abstract_t">Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 2011; 12:997.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208630s000lbl.pdf.</li><li><a class="nounderline abstract_t">Hadjipanayis CG, Stummer W. 5-ALA and FDA approval for glioma surgery. J Neurooncol 2019; 141:479.</a></li><li><a class="nounderline abstract_t">Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7:392.</a></li><li><a class="nounderline abstract_t">Pichlmeier U, Bink A, Schackert G, et al. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 2008; 10:1025.</a></li><li><a class="nounderline abstract_t">Mansouri A, Mansouri S, Hachem LD, et al. The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: A systematic review. Cancer 2016; 122:2469.</a></li><li><a class="nounderline abstract_t">Stummer W, Stepp H, Wiestler OD, Pichlmeier U. Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas. Neurosurgery 2017; 81:230.</a></li><li><a class="nounderline abstract_t">Eatz TA, Eichberg DG, Lu VM, et al. Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review. J Neurooncol 2022; 156:233.</a></li><li><a class="nounderline abstract_t">Roder C, Stummer W, Coburger J, et al. Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial. J Clin Oncol 2023; 41:5512.</a></li><li><a class="nounderline abstract_t">Nickel K, Renovanz M, König J, et al. The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study. Neurosurg Rev 2018; 41:207.</a></li><li><a class="nounderline abstract_t">Dinapoli RP, Brown LD, Arusell RM, et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 1993; 11:1316.</a></li><li><a class="nounderline abstract_t">Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 1991; 29:385.</a></li><li><a class="nounderline abstract_t">Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993; 78:762.</a></li><li><a class="nounderline abstract_t">Sandberg-Wollheim M, Malmström P, Strömblad LG, et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991; 68:22.</a></li><li><a class="nounderline abstract_t">Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993; 78:767.</a></li><li><a class="nounderline abstract_t">Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26:239.</a></li><li><a class="nounderline abstract_t">Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95:190.</a></li><li><a class="nounderline abstract_t">Bucci MK, Maity A, Janss AJ, et al. Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era. Cancer 2004; 101:817.</a></li><li><a class="nounderline abstract_t">Kreth FW, Thon N, Simon M, et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol 2013; 24:3117.</a></li><li><a class="nounderline abstract_t">Molinaro AM, Hervey-Jumper S, Morshed RA, et al. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncol 2020; 6:495.</a></li><li><a class="nounderline abstract_t">Gerritsen JKW, Zwarthoed RH, Kilgallon JL, et al. Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups. Neuro Oncol 2023; 25:958.</a></li><li><a class="nounderline abstract_t">Noorbakhsh A, Tang JA, Marcus LP, et al. Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. J Neurosurg 2014; 120:31.</a></li><li><a class="nounderline abstract_t">Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol 2014; 16:113.</a></li><li><a class="nounderline abstract_t">Karschnia P, Young JS, Dono A, et al. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neuro Oncol 2023; 25:940.</a></li><li><a class="nounderline abstract_t">Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 2014; 16:81.</a></li><li><a class="nounderline abstract_t">Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5:79.</a></li><li><a class="nounderline abstract_t">Dixit S, Hingorani M, Achawal S, Scott I. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without previous gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas: in regard to Noel et al. (Int J Radiat Oncol Biol Phys 2011; DOI: 10.1016/j.ijrobp.2010.11.073). Int J Radiat Oncol Biol Phys 2011; 81:1593.</a></li><li><a class="nounderline abstract_t">Pallud J, Audureau E, Noel G, et al. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. Neuro Oncol 2015; 17:1609.</a></li><li><a class="nounderline abstract_t">Duntze J, Litré CF, Eap C, et al. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann Surg Oncol 2013; 20:2065.</a></li><li><a class="nounderline abstract_t">Burri SH, Prabhu RS, Sumrall AL, et al. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial. J Neurooncol 2015; 123:259.</a></li></ol></div><div id="topicVersionRevision">Topic 5228 Version 58.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15687310" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Patterns of care for adults with newly diagnosed malignant glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16431108" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Leptomeningeal infiltration as the presenting manifestation of a malignant glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24620869" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Case records of the Massachusetts General Hospital. Case 8-2014. A 29-year-old man with headache, vomiting, and diplopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17047647" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17290068" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cerebrospinal fluid spread of anaplastic glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12297589" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : How often are nonenhancing supratentorial gliomas malignant? A population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34174071" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34174071" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34185076" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33215342" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28339700" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26287849" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30351999" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33646525" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30220707" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30344944" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29323298" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A metabolic function of FGFR3-TACC3 gene fusions in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16509497" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Frameless image-guided stereotactic brain biopsy procedure: diagnostic yield, surgical morbidity, and comparison with the frame-based technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11859971" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Metastatic seeding of the stereotactic biopsy tract in glioblastoma multiforme: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9524102" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Iatrogenic seeding of anaplastic astrocytoma following stereotactic biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15299051" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12405365" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12570135" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Influence of 1.5-Tesla intraoperative MR imaging on surgical decision making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12546355" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33215341" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cytoreductive surgery in the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27310651" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28427986" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prognostic Implications of Extent of Resection in Glioblastoma: Analysis from a Large Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15701282" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16509498" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15458599" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Functional magnetic resonance imaging-integrated neuronavigation: correlation between lesion-to-motor cortex distance and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15567548" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Magnetic source imaging supports clinical decision making in glioma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34060940" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Can Preoperative Mapping with Functional MRI Reduce Morbidity in Brain Tumor Resection? A Systematic Review and Meta-Analysis of 68 Observational Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17236493" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Visualization of the frontotemporal language fibers by tractography combined with functional magnetic resonance imaging and magnetoencephalography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29355914" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intraoperative imaging technology to maximise extent of resection for glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29125414" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Resection of gliomas deemed inoperable by neurosurgeons based on preoperative imaging studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25909573" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Awake craniotomy to maximize glioma resection: methods and technical nuances over a 27-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172171" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Functional outcome after language mapping for glioma resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868286" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33428222" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intraoperative imaging technology to maximise extent of resection for glioma: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868284" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868284" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30644008" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : 5-ALA and FDA approval for glioma surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648043" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18667747" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27183272" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28379547" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34989964" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37335962" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28265818" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315428" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1833663" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8385709" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2049748" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8468607" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8387988" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11780887" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15305415" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24130262" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32027343" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36420703" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24205904" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24285550" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35961053" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24305719" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672279" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22115561" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without previous gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas: in regard to Noel et al. (Int J Radiat Oncol Biol Phys 2011; DOI: 10.1016/j.ijrobp.2010.11.073).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26185110" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23212763" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25947286" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
